The “Metastatic Colorectal cancer – Pipeline Insight, 2022” drug pipelines have been added to ResearchAndMarkets.com’s offering.
The publisher’s, “Metastatic Colorectal cancer – Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape.
It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Metastatic Colorectal Cancer pipeline landscape is provided which includes the disease overview and Metastatic Colorectal cancer treatment guidelines. The assessment part of the report embraces, a depth Metastatic Colorectal cancer commercial assessment and clinical assessment of the pipeline products under development.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In the report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal cancer collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Colorectal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Colorectal cancer.
- On November 18, 2021, Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
- In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
- In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus’ balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech’s clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
- On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
- In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
- In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.
Source: Businesswire
